期刊文献+

重组生长激素体外干预人肝癌细胞膜GHR密度变化 被引量:2

Effects of Recombinant Human Growth Hormone on the Expression of GHR of Human Liver Cancer Cell in Vitro
下载PDF
导出
摘要 目的体外环境下,针对人肝癌细胞生长激素受体(GHR)的不同表达状态,研究重组人生长激素(rhGH)对其胞膜表面GHR密度变化的影响。方法采用免疫细胞化学方法分别半定量测定人肝癌细胞株HepG2、SMMC7721、和QGY7701的GHR表达情况,采取50ng/mLrhGH,100ng/mLrhGH,200ng/mLrhGH干预和未处理4种干预方式体外培养上述3种细胞,然后利用放射性受体分析方法定量检测胞膜表面GHR密度变化。结果免疫细胞化学检测细胞株HepG2呈GHR高表达状态,50ng/mLrhGH、100ng/mLrhGH、200ng/mLrhGH干预后胞膜表面GHR位点数分别为8.4350±0.2396、9.3957±0.5143、8.3297±0.3133(10^3/cell),较空白对照组7.5137±0.5352(10^3/cell)明显增加(P〈0.05);细胞株SMMC7721呈GHR弱表达状态,50ng/mLrhGH、100ng/mLrhGH、200ng/mLrhGH干预后胞膜表面GHR位点数分别为3.8343±0.2590、3.8213±0.2276、3.6947±0.2722(10^3/cell),与空白对照组3.7190±0.2824(10^3/cell)差异无统计学意义(P〉0.05);细胞株QGY7701未表达GHR,各种rhGH干预后均未出现GHR表达的现象。结论rhGH明显促GHR高表达细胞株HepG2胞膜表面GHR密度增加,对GHR低表达细胞株SMMC772胞膜表面GHR密度无影响。rhGH不会改变细胞株QGY7701的GHR不表达状态。 Objective Purpose To investigate the effects of recombinant human growth hormone (rhGH) on human liver cancer expressed diffferent growth hormone receptor(GHR) in vitro. Methods The expression of GHR in human liver cancer cell lines was detected by immunohistochemistry and radioligand assays. Four groups were assigned according to the cell line treatment modes: untreated group, 50 ng/mL rhGH treated group,100 ng/mL rhGH treated group,200ng/mL rhGH treated group. Results In HepG2 which GHR was high-expressed: compared with the untreated group in which the GHR site was 7. 513 7 ±0. 535 2( 10^3/cell), expressions of GHR were significantly increased in the treated groups : the sites of 50ng/mL rhGH treated group, 100 ng/mL rhGH treated group,200 ng/mL rhGH treated group were 8.435 0 ±0. 239 6,9. 395 7 ±0. 514 3, 8. 329 7 ± 0.313 3 (10^3/cell) ( P 〈 0.05 ). SMMC7721 in which GHR was low-expressed: compared with the untreated group of which the GHR site was 3.719 0 ± 0. 282 4 ( 10^3/cell), there was no remarkable effect on the treated groups:the sites of 50 ng/mL rhGH treated group, 100 ng/mL rhGH treated group, 200 ng/mL rhGH treated group were 3. 834 3 ±0. 259 0、3. 821 3±0. 227 6,3. 694 7 ±0. 272 2 (10^3/cell) (P 〉0.05). QGY7701 always had no expression of GHR no matter it was treated with different concentrations. Conclusions rhGH can stimulate the expression of GHR in which GHR was high-expressed such as HepG2. However, such effect was not remarkable for tumor cells in which GHR was low-expressed or no-expressed in vitro.
出处 《中国肿瘤外科杂志》 CAS 2009年第1期44-47,共4页 Chinese Journal of Surgical Oncology
基金 南京市医学科技发展项目计划专项基金资助项目(YKK07097)
关键词 重组人生长激素 生长激素受体 肝癌 rhGH GHR liver neoplasm
  • 相关文献

参考文献4

  • 1郭爱平,李苏宜.重组人生长激素联合奈达铂在体外对人食管癌细胞株EC109作用的实验研究[J].现代医学,2007,35(5):370-374. 被引量:6
  • 2Jana Divisova,Isere Kuiatse,ZaWaunyka Lazard,Heidi Weiss,Franzanne Vreeland,Darryl L. Hadsell,Rachel Schiff,C. Kent Osborne,Adrian V. Lee.The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth[J].Breast Cancer Research and Treatment.2006(3)
  • 3Clausen Lene R,Kristiansen Mikkel T,Rasmussen Lars M,Billestrup Nils,Blaabjerg Ole,Ledet Thomas,J?rgensen Jens O L.Growth hormone receptor expression and function in pituitary adenomas[].Clinical Endocrinology.2004
  • 4Yin Donghua,Vreeland Franzanne,Schaaf Larry J,Millham Robert,Duncan Barbara A,Sharma Amarnath.Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy[].Clinical cancer research : an official journal of the American Association for Cancer Research.2007

二级参考文献10

  • 1[1]Harrison L E,Brennan M F.The role of total parenteral nutrition in the patient with cancer[J].Current Problems in Surgery,1995,32(10):837-840.
  • 2[3]Snibson K J,Bhathal P S,Adams T E.Overexpressed growth hormone(GH) synergistically promotes carcinogen-initiated liver tumour growth by promoting cellular proliferation in emerging hepatocellular neoplasms in female and male GH-transgenic mice[J].Liver,2001,21(2):149-158.
  • 3[4]Ergun-Longmire B,Mertens A C,Mitby P,et al.Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor[J].J Clin Endocrinol Metab,2006,91(9):3494-3498.
  • 4[5]Fiebig H H,Dengler W,Hendriks H R,et al.No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone[J].Anti-cancer Drug,2000,11(8):659-664.
  • 5[7]Solar C A,Mertens A C,Mitby P,et al.Risk of disease recurrence and second neoplasms in survivors of childhood cancer treatment with growth hormone:a report from the childhood cancer survivors study[J].J Clin Endocrinol Metab,2002,87(7):3136-3141.
  • 6[8]Tacke J,Bolder U,Herrmann A,et al.Long-term risk of gastro-intestinal tumor recurrence after postoperative treatment with recombinant human growth hormone[J].J Parenteral Enteral Nutr,2000,24(3):140-144.
  • 7[9]Desoize B,Madoulet C.Particular aspects of platinum compounds used at present in cancer treatment[J].Crit Rev Oncol Hematol,2002,42(3):317-325.
  • 8[10]Gebre-Medhin M,Kindb L G,Wennbo H,et al.Growth hormone receptor is expressed in human breast cancer[J].Am J Pathol,2001,158(4):1217-1222.
  • 9吴文溪 许勤 郭家骅 等.生长激素联合早期腹腔化疗对小鼠结肠腺癌肝转移的影响[J].肠外与肠内营养,2000,7(4):246-246.
  • 10石毅,廖泉,陈革,赵玉沛.生长激素受体在胰腺癌细胞的表达及生长激素对胰腺癌细胞周期的影响[J].中华实验外科杂志,2004,21(4):441-443. 被引量:22

共引文献5

同被引文献44

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部